SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Duke Kahanamoku Synthetic CCD — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientDuke Kahanamoku
Date of birth1890-08-24
IdentifiersMRN HR-ML050-SYN-TD; SSN (made up) 000-50-6847
Document date2026-11-01
AuthorKawika Lindgren-Morrison, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

Establishing care for six weeks of breathlessness, ankle swelling and tiredness five years after a heart attack: examination, ECG, chest X-ray, NT-proBNP and laboratory tests, a diuretic, and the plan for an echocardiogram. Concerns: He wants to get back in the ocean, to swim and surf again; He wants to keep working as sheriff; He wants his ʻohana involved as he chooses and his own ways of healing respected. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Aspirin 81 mg delayed-release oral tablet, one tablet dailyOne tablet dailyOral route1952-06-21activeS
Atorvastatin 40 mg oral tablet, one tablet dailyOne tablet dailyOral route1952-06-21 to 1957-03-16completedS
Atorvastatin 80 mg oral tablet, one tablet dailyOne tablet dailyOral route1957-03-16activeS
Metoprolol tartrate 25 mg oral tablet, one tablet twice dailyOne tablet twice dailyOral route1952-06-21 to 1957-03-30completedS
Lisinopril 10 mg oral tablet, one tablet dailyOne tablet dailyOral route1952-06-21 to 1957-03-30completedS
Furosemide 40 mg oral tablet, one tablet every morningOne tablet every morningOral route1957-03-16 to 1957-04-27completedS
Furosemide 20 mg oral tablet, one tablet every morningOne tablet every morningOral route1957-04-27activeS
Sacubitril 24 mg / valsartan 26 mg oral tablet, one tablet twice daily, first dose 36 hours after the last lisinoprilOne tablet twice dailyOral route1957-03-30 to 1957-09-28completedS
Sacubitril 49 mg / valsartan 51 mg oral tablet, one tablet twice dailyOne tablet twice dailyOral route1957-09-28activeS
Carvedilol 3.125 mg oral tablet, one tablet twice daily with food, starting the evening after the last metoprolol tartrateOne tablet twice daily with foodOral route1957-03-30 to 1957-04-13completedS
Carvedilol 6.25 mg oral tablet, one tablet twice daily with foodOne tablet twice daily with foodOral route1957-04-13 to 1957-04-27completedS
Carvedilol 12.5 mg oral tablet, one tablet twice daily with foodOne tablet twice daily with foodOral route1957-04-27activeS
Empagliflozin 10 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating or drinkingOne tablet daily, with sick-day rulesOral route1957-03-30activeS
Spironolactone 25 mg oral tablet, one-half tablet (12.5 mg) dailyOne-half tablet dailyOral route1957-04-13activeS
Ferric carboxymaltose 750 mg (15 mL vial, 50 mg/mL) by intravenous infusion, two doses two weeks apartTwo infusions two weeks apartIntravenous route1957-03-30 to 1957-04-13completedS

Procedures

ProcedureDatesStatusEvidence
Twelve-lead electrocardiogram: sinus rhythm at 92 per minute, Q waves in V1 to V4 from an old anterior infarction, QRS 104 ms, no left bundle branch block, no atrial fibrillation1957-03-16 to 1957-03-16completedS
Chest X-ray, two views: enlarged heart, upper-lobe venous diversion and small pleural effusions on both sides; no pneumonia1957-03-16 to 1957-03-16completedS
Transthoracic echocardiography: ejection fraction 30% by biplane method, thinned and akinetic anterior wall and apex, no left ventricular thrombus, dilated left ventricle (end-diastolic diameter 62 mm), moderate functional mitral regurgitation, normal right ventricle, estimated pulmonary artery systolic pressure 42 mmHg1957-03-30 to 1957-03-30completedS
Invasive coronary angiography by the radial route: chronic total occlusion of the proximal left anterior descending artery filling faintly by collaterals from the right coronary artery, 40% narrowing of the mid right coronary artery and 30% of the circumflex; no lesion suitable for or likely to benefit from revascularization, given the thinned, scarred anterior wall1957-04-06 to 1957-04-06completedS
Twelve-lead electrocardiogram at the sick visit: sinus rhythm at 96 per minute, old anterior Q waves unchanged, no peaked T waves, no change in QRS width1957-04-22 to 1957-04-22completedS
Outpatient cardiac rehabilitation for heart failure: 36 sessions over twelve weeks, with supervised pool swimming in the last month and an ocean-safety plan; all sessions completed1957-05-26 to 1957-08-14completedS
Advance care planning conversation, about 25 minutes, with his consent1957-09-14 to 1957-09-14completedS
Transthoracic echocardiography after more than 90 days of therapy: ejection fraction 38% by biplane method, anterior wall and apex still thinned and akinetic, left ventricular end-diastolic diameter 58 mm (from 62), mild mitral regurgitation (from moderate), no thrombus, estimated pulmonary artery systolic pressure 30 mmHg1957-09-28 to 1957-09-28completedS

Immunizations

DateVaccineStatusEvidence
1957-03-30Pneumococcal conjugate vaccine PCV20completedS
1957-09-14High-dose influenza vaccine, this seasoncompletedS
1957-09-14Respiratory syncytial virus vaccine, single dosecompletedS
1957-09-14COVID-19 vaccine, mRNA, this seasoncompletedS
1957-09-28Recombinant zoster vaccine, dose 1 of 2completedS
1957-09-28Tetanus, diphtheria, and acellular pertussis vaccine (Tdap)completedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

Historical dateHistoryEvidence
1952Heart attack in 1952, at about 61, one of several in his later years; details of its treatment are not recorded in the sources readD (CLM-0009)

Family History

No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.

Health Concerns

ConcernStatusEvidence
He wants to get back in the ocean, to swim and surf againactiveS
He wants to keep working as sheriffactiveS
He wants his ʻohana involved as he chooses and his own ways of healing respectedactiveS

Assessment

Most recent measures: Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma 620 on 1957-09-28; Sodium [Moles/volume] in Serum or Plasma 138 on 1957-09-28; Potassium [Moles/volume] in Serum or Plasma 4.6 on 1957-09-28; Creatinine [Mass/volume] in Serum or Plasma 1.14 on 1957-09-28; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1952)/1.73 sq M 70 on 1957-09-28; Glucose [Mass/volume] in Serum or Plasma 95 on 1957-09-28; Magnesium [Mass/volume] in Serum or Plasma 2 on 1957-09-28; Hemoglobin [Mass/volume] in Blood 14.1 on 1957-09-28; Ferritin [Mass/volume] in Serum or Plasma 248 on 1957-09-28; Iron saturation [Mass Fraction] in Serum or Plasma 27 on 1957-09-28; Thyrotropin [Units/volume] in Serum or Plasma 2.1 on 1957-03-16; Hemoglobin A1c/Hemoglobin.total in Blood 5.9 on 1957-03-16; Cholesterol [Mass/volume] in Serum or Plasma 130 on 1957-04-27; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 62 on 1957-04-27; Cholesterol in HDL [Mass/volume] in Serum or Plasma 45 on 1957-04-27; Triglyceride [Mass/volume] in Serum or Plasma 115 on 1957-04-27; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 31 on 1957-04-27; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 1957-09-14; Overall summary score [KCCQ-12] 80 on 1957-09-28; Left ventricular Ejection fraction 38 on 1957-09-28; Total score [Mini-Cog] 5 on 1957-09-14; Total score [AUDIT-C] 0 on 1957-09-14 [S]

Strengths and supports: engagement in care [S]

Problems

ProblemClinical statusVerificationCodeProvenance
Breathlessness on exertion for six weeks (paddling out, walking uphill, finishing his morning swim), with ankle swelling by evening and tiredness, five years after a heart attack; cause to be determinedresolvedconfirmed R06.09S — Synthetic presenting problem, resolved at the second visit when the echocardiogram and cardiology established heart failure with reduced ejection fraction.
Coronary artery disease with an old anterior myocardial infarction five years ago, treated with medicines; synthetic modern episode linked to the documented heart attack of 1883activeconfirmed I25.2S — Synthetic modern diagnosis; the 1952 heart attack remains D in the history.
Heart failure with reduced ejection fraction from ischemic cardiomyopathy (ejection fraction 30% with a thinned, akinetic anterior wall and apex), NYHA class III at diagnosisactiveconfirmed I50.22S — Synthetic modern diagnosis made at the second visit; no claim that he had heart failure in his lifetime.
Iron deficiency without anemia (ferritin 62 ng/mL, transferrin saturation 16%)activeconfirmed E61.1S — Synthetic finding at the heart failure workup.
Viral gastroenteritis for two days, with volume depletion, potassium 5.5 mmol/L and a rise in creatinine on sacubitril-valsartan, spironolactone, empagliflozin and furosemide; settled with sick-day rulesresolvedconfirmed A08.4S — Synthetic intercurrent problem at an unscheduled visit; it follows from his heart failure medicines and does not echo a documented illness.

Results

DateMeasureValueUnitReference rangeFlagProvenance
1957-03-16Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma2450pg/mLBelow 125 pg/mL makes heart failure unlikely outside the hospitalHighS
1957-03-16Sodium [Moles/volume] in Serum or Plasma138mmol/L135-145 mmol/LNormalS
1957-03-16Potassium [Moles/volume] in Serum or Plasma4.2mmol/L3.5-5.1 mmol/LNormalS
1957-03-16Creatinine [Mass/volume] in Serum or Plasma1.02mg/dL0.74-1.35 mg/dLNormalS
1957-03-16Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1952)/1.73 sq M81mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1957-03-16Glucose [Mass/volume] in Serum or Plasma102mg/dL70-99 mg/dLHighS
1957-03-16Magnesium [Mass/volume] in Serum or Plasma2mg/dL1.6-2.6 mg/dLNormalS
1957-03-16Hemoglobin [Mass/volume] in Blood13.4g/dL13.2-16.6 g/dLNormalS
1957-03-16Ferritin [Mass/volume] in Serum or Plasma62ng/mLIn heart failure, below 100 ng/mL, or 100 to 299 with transferrin saturation below 20%, is iron deficiencyLowS
1957-03-16Iron saturation [Mass Fraction] in Serum or Plasma16%20-50%LowS
1957-03-16Thyrotropin [Units/volume] in Serum or Plasma2.1m[IU]/L0.45-4.5 mIU/LNormalS
1957-03-16Hemoglobin A1c/Hemoglobin.total in Blood5.9%<=5.6%HighS
1957-03-16Cholesterol [Mass/volume] in Serum or Plasma168mg/dL<=199 mg/dLNormalS
1957-03-16Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation92mg/dLSecondary-prevention goal below 70 mg/dLHighS
1957-03-16Cholesterol in HDL [Mass/volume] in Serum or Plasma44mg/dL>=40 mg/dLNormalS
1957-03-16Triglyceride [Mass/volume] in Serum or Plasma160mg/dL<=149 mg/dLHighS
1957-03-16Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma28U/L7-55 U/LNormalS
1957-03-16Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S
1957-03-16Overall summary score [KCCQ-12]38{score}S
1957-03-30Sodium [Moles/volume] in Serum or Plasma137mmol/L135-145 mmol/LNormalS
1957-03-30Potassium [Moles/volume] in Serum or Plasma3.9mmol/L3.5-5.1 mmol/LNormalS
1957-03-30Creatinine [Mass/volume] in Serum or Plasma1.08mg/dL0.74-1.35 mg/dLNormalS
1957-03-30Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1952)/1.73 sq M76mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1957-03-30Glucose [Mass/volume] in Serum or Plasma98mg/dL70-99 mg/dLNormalS
1957-03-30Magnesium [Mass/volume] in Serum or Plasma1.9mg/dL1.6-2.6 mg/dLNormalS
1957-03-30Left ventricular Ejection fraction30%50-70%LowS
1957-04-13Sodium [Moles/volume] in Serum or Plasma137mmol/L135-145 mmol/LNormalS
1957-04-13Potassium [Moles/volume] in Serum or Plasma4.5mmol/L3.5-5.1 mmol/LNormalS
1957-04-13Creatinine [Mass/volume] in Serum or Plasma1.16mg/dL0.74-1.35 mg/dLNormalS
1957-04-13Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1952)/1.73 sq M69mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1957-04-13Glucose [Mass/volume] in Serum or Plasma96mg/dL70-99 mg/dLNormalS
1957-04-13Magnesium [Mass/volume] in Serum or Plasma2mg/dL1.6-2.6 mg/dLNormalS
1957-04-13Overall summary score [KCCQ-12]56{score}S
1957-04-22Sodium [Moles/volume] in Serum or Plasma133mmol/L135-145 mmol/LLowS
1957-04-22Potassium [Moles/volume] in Serum or Plasma5.5mmol/L3.5-5.1 mmol/LHighS
1957-04-22Creatinine [Mass/volume] in Serum or Plasma1.52mg/dL0.74-1.35 mg/dLHighS
1957-04-22Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1952)/1.73 sq M50mL/min/{1.73_m2}>=60 mL/min/1.73 m²LowS
1957-04-22Glucose [Mass/volume] in Serum or Plasma88mg/dL70-99 mg/dLNormalS
1957-04-22Magnesium [Mass/volume] in Serum or Plasma2.1mg/dL1.6-2.6 mg/dLNormalS
1957-04-27Sodium [Moles/volume] in Serum or Plasma137mmol/L135-145 mmol/LNormalS
1957-04-27Potassium [Moles/volume] in Serum or Plasma4.8mmol/L3.5-5.1 mmol/LNormalS
1957-04-27Creatinine [Mass/volume] in Serum or Plasma1.2mg/dL0.74-1.35 mg/dLNormalS
1957-04-27Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1952)/1.73 sq M67mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1957-04-27Glucose [Mass/volume] in Serum or Plasma97mg/dL70-99 mg/dLNormalS
1957-04-27Magnesium [Mass/volume] in Serum or Plasma2mg/dL1.6-2.6 mg/dLNormalS
1957-04-27Cholesterol [Mass/volume] in Serum or Plasma130mg/dL<=199 mg/dLNormalS
1957-04-27Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation62mg/dLSecondary-prevention goal below 70 mg/dLNormalS
1957-04-27Cholesterol in HDL [Mass/volume] in Serum or Plasma45mg/dL>=40 mg/dLNormalS
1957-04-27Triglyceride [Mass/volume] in Serum or Plasma115mg/dL<=149 mg/dLNormalS
1957-04-27Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma31U/L7-55 U/LNormalS
1957-04-27Overall summary score [KCCQ-12]66{score}S
1957-09-14Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S
1957-09-28Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma620pg/mLBelow 125 pg/mL makes heart failure unlikely outside the hospitalHighS
1957-09-28Sodium [Moles/volume] in Serum or Plasma138mmol/L135-145 mmol/LNormalS
1957-09-28Potassium [Moles/volume] in Serum or Plasma4.6mmol/L3.5-5.1 mmol/LNormalS
1957-09-28Creatinine [Mass/volume] in Serum or Plasma1.14mg/dL0.74-1.35 mg/dLNormalS
1957-09-28Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1952)/1.73 sq M70mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1957-09-28Glucose [Mass/volume] in Serum or Plasma95mg/dL70-99 mg/dLNormalS
1957-09-28Magnesium [Mass/volume] in Serum or Plasma2mg/dL1.6-2.6 mg/dLNormalS
1957-09-28Hemoglobin [Mass/volume] in Blood14.1g/dL13.2-16.6 g/dLNormalS
1957-09-28Ferritin [Mass/volume] in Serum or Plasma248ng/mLIn heart failure, below 100 ng/mL, or 100 to 299 with transferrin saturation below 20%, is iron deficiencyNormalS
1957-09-28Iron saturation [Mass Fraction] in Serum or Plasma27%20-50%NormalS
1957-09-28Left ventricular Ejection fraction38%50-70%LowS
1957-09-28Overall summary score [KCCQ-12]80{score}S
1957-09-14Total score [Mini-Cog]5{score}S
1957-09-14Total score [AUDIT-C]0{score}S

Social History

Vital Signs

DateMeasureValueUnitProvenance
1957-03-16Body height185cmS
1957-03-16Body weight97.6kgS
1957-03-16Body mass index (BMI) [Ratio]28.5kg/m2S
1957-03-16Systolic blood pressure142mm[Hg]S
1957-03-16Diastolic blood pressure86mm[Hg]S
1957-03-16Heart rate92/minS
1957-03-16Respiratory rate20/minS
1957-03-16Body temperature36.7CelS
1957-03-16Oxygen saturation in Arterial blood by Pulse oximetry94%S
1957-03-30Body height185cmS
1957-03-30Body weight95kgS
1957-03-30Body mass index (BMI) [Ratio]27.8kg/m2S
1957-03-30Systolic blood pressure134mm[Hg]S
1957-03-30Diastolic blood pressure82mm[Hg]S
1957-03-30Heart rate86/minS
1957-03-30Respiratory rate18/minS
1957-03-30Body temperature36.6CelS
1957-03-30Oxygen saturation in Arterial blood by Pulse oximetry96%S
1957-04-13Body height185cmS
1957-04-13Body weight93.6kgS
1957-04-13Body mass index (BMI) [Ratio]27.3kg/m2S
1957-04-13Systolic blood pressure118mm[Hg]S
1957-04-13Diastolic blood pressure72mm[Hg]S
1957-04-13Heart rate74/minS
1957-04-13Respiratory rate16/minS
1957-04-13Body temperature36.6CelS
1957-04-13Oxygen saturation in Arterial blood by Pulse oximetry97%S
1957-04-27Body height185cmS
1957-04-27Body weight93kgS
1957-04-27Body mass index (BMI) [Ratio]27.2kg/m2S
1957-04-27Systolic blood pressure112mm[Hg]S
1957-04-27Diastolic blood pressure70mm[Hg]S
1957-04-27Heart rate68/minS
1957-04-27Respiratory rate16/minS
1957-04-27Body temperature36.6CelS
1957-04-27Oxygen saturation in Arterial blood by Pulse oximetry97%S
1957-09-28Body height185cmS
1957-09-28Body weight92.8kgS
1957-09-28Body mass index (BMI) [Ratio]27.1kg/m2S
1957-09-28Systolic blood pressure106mm[Hg]S
1957-09-28Diastolic blood pressure66mm[Hg]S
1957-09-28Heart rate64/minS
1957-09-28Respiratory rate16/minS
1957-09-28Body temperature36.5CelS
1957-09-28Oxygen saturation in Arterial blood by Pulse oximetry98%S
1957-04-22Body height185cmS
1957-04-22Body weight91.4kgS
1957-04-22Body mass index (BMI) [Ratio]26.7kg/m2S
1957-04-22Systolic blood pressure102mm[Hg]S
1957-04-22Diastolic blood pressure62mm[Hg]S
1957-04-22Heart rate96/minS
1957-04-22Respiratory rate16/minS
1957-04-22Body temperature37.6CelS
1957-04-22Oxygen saturation in Arterial blood by Pulse oximetry97%S
1957-09-14Body height185cmS
1957-09-14Body weight92.6kgS
1957-09-14Body mass index (BMI) [Ratio]27.1kg/m2S
1957-09-14Systolic blood pressure108mm[Hg]S
1957-09-14Diastolic blood pressure68mm[Hg]S
1957-09-14Heart rate64/minS
1957-09-14Respiratory rate16/minS
1957-09-14Body temperature36.6CelS
1957-09-14Oxygen saturation in Arterial blood by Pulse oximetry98%S

Encounters

DatePurposeStatusProvenance
1957-03-16Establishing care for six weeks of breathlessness, ankle swelling and tiredness five years after a heart attack: examination, ECG, chest X-ray, NT-proBNP and laboratory tests, a diuretic, and the plan for an echocardiogramfinishedS
1957-03-30Two-week review: echocardiogram, heart failure cardiology consultation the same day, the diagnosis, and guideline-directed medicinesfinishedS
1957-04-13Two-week review after sacubitril-valsartan, carvedilol and empagliflozin: kidney function, potassium, angiography result and the next medicinefinishedS
1957-04-27Two-week review, five days after the sick visit: kidney function and potassium, medicine doses, lipids, and cardiac rehabilitation adapted to the oceanfinishedS
1957-09-28Six-month review: repeat echocardiogram after more than 90 days of therapy, the defibrillator decision, iron, the delayed titration step, and plans for the yearfinishedS
1957-04-22Same-day sick visit for vomiting and diarrhea on heart failure medicinesfinishedS
1957-09-14Subsequent annual wellness visitfinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Culturally safe care: address him as Mr. Kahanamoku, as he asked; take time; explain each test and medicine plainly; involve his ʻohana as he chooses while he makes the decisionscompletedGL-KEOLAMAMO, GL-NH-HF-2015S
Heart failure cardiology consultation on the day of the two-week visit, with an echocardiogram, to confirm the diagnosis and its cause and to plan guideline-directed medical therapy, ischemic evaluation and device decisionscompletedGL-HF-2022, GL-HFREF-ECDP-2024, GL-CMID-2026S
Furosemide 40 mg every morning for congestion, with a daily weight and a written plan; metabolic panel and magnesium in one to two weeks; lower the dose when he is drycompletedGL-HF-2022, GL-CMID-2026S
Baseline tests: ECG, chest X-ray, NT-proBNP, metabolic panel and magnesium, blood count, iron studies, TSH, hemoglobin A1c, lipids and ALT; echocardiogram at the two-week visitcompletedGL-HF-2022, GL-CMID-2026S
Atorvastatin raised from 40 to 80 mg for LDL 92 mg/dL; lipid panel in four to twelve weeks; goal below 70 mg/dLcompletedGL-CCD-2023, GL-CMID-2026S
Sodium: less salted and dried fish, shoyu and salty party food, using the foods he already eats; no routine fluid restriction; daily weightscompletedGL-HF-2022S
Vaccinations: pneumococcal, influenza, COVID-19 and RSV as due, because heart disease raises the risk of severe respiratory infectioncompletedGL-HF-2022, GL-CDC-IMZ-2026S
Native Hawaiian healing alongside clinic care, if he wishes: lomilomi through Ke Ola Mamo, a Native Hawaiian Health Care System; he will tell the clinic before using any plant medicine so that interactions can be checked; the clinic asks nothing further about his practicescompletedGL-KEOLAMAMOS
Guideline-directed medical therapy: stop lisinopril and start sacubitril-valsartan 24/26 mg twice daily 36 hours after the last dose; change metoprolol tartrate to carvedilol 3.125 mg twice daily; empagliflozin 10 mg daily; add spironolactone when potassium and kidney function allow; raise one medicine every two weeks toward target doses, with a metabolic panel one to two weeks after each changecompletedGL-HF-2022, GL-HFREF-ECDP-2024, GL-CMID-2026S
Intravenous ferric carboxymaltose 750 mg at the two-week visit and again two weeks later, for iron deficiency in heart failure with reduced ejection fraction; iron studies again at about six monthscompletedGL-HF-2022, GL-CMID-2026S
Invasive coronary angiography within two weeks to define the coronary disease and whether revascularization could helpcompletedGL-HF-2022, GL-CCD-2023S
Defibrillator decision: repeat echocardiogram after at least 90 days of optimized therapy; a primary-prevention ICD if the ejection fraction stays at 35% or below with NYHA class II to IIIcompletedGL-HF-2022, GL-VA-ICD-2017, GL-CMID-2026S
Sick-day rules: on days of vomiting, diarrhea or not drinking, hold empagliflozin, furosemide, spironolactone and sacubitril-valsartan, keep carvedilol if blood pressure allows, drink small amounts often, and restart when eating and drinking normally for a day; a written cardcompletedGL-HF-2022, GL-HFREF-ECDP-2024S
Cardiac rehabilitation for heart failure, 36 sessions, adapted to an ocean athlete: pool swimming in the program, then calm water inside the reef with a companion and near a lifeguard, no breath-hold diving, no big surf until cleared, water through the morning, and out of the water at once for chest pain, lightheadedness or unusual breathlessnesscompletedGL-HF-2022, GL-CMID-2026S
Laboratory tests drawn at the clinic on the day of each medicine change or by the clinic's nurse at home, with nurse calls to titrate doses between visitscompletedGL-HFREF-ECDP-2024, GL-CMID-2026S

Goals

GoalTargetStatusOutcomeProvenance
Euvolemia: no ankle swelling or orthopnea, with a steady dry weight1957-04-27completedDry weight about 93 kg; no edema or orthopnea; furosemide reduced to 20 mgS
All four guideline-directed medicines at the highest doses he tolerates within three months1957-09-28activeAll four classes started within two weeks of diagnosis; carvedilol 12.5 mg twice daily, empagliflozin and spironolactone at their doses; sacubitril-valsartan stayed at the starting dose for five months after a missed titration step and was raised at six monthsS
KCCQ-12 at least 20 points higher and NYHA class I to II within six months1957-09-28completedKCCQ-12 38 to 80; NYHA class I to IIS
Back in the ocean safely, swimming in calm water with a companion1957-09-28completedSwimming three mornings a week in calm water inside the reef with a friend, after cardiac rehabilitationS
LDL cholesterol below 70 mg/dL1957-04-27completedLDL 62 mg/dL on atorvastatin 80 mgS

Functional Status

Mental Status